Zhizhuang Zhao to Polycythemia Vera
This is a "connection" page, showing publications Zhizhuang Zhao has written about Polycythemia Vera.
Connection Strength
2.342
-
Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera. PLoS One. 2020; 15(6):e0232801.
Score: 0.700
-
Elevated levels of mast cells are involved in pruritus associated with polycythemia vera in JAK2V617F transgenic mice. J Immunol. 2014 Jul 15; 193(2):477-84.
Score: 0.462
-
Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem. 2007 Feb 09; 282(6):3428-32.
Score: 0.275
-
Role of tyrosine kinases and phosphatases in polycythemia vera. Semin Hematol. 2005 Oct; 42(4):221-9.
Score: 0.253
-
Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005 Jun 17; 280(24):22788-92.
Score: 0.246
-
PTP-MEG2 is activated in polycythemia vera erythroid progenitor cells and is required for growth and expansion of erythroid cells. Blood. 2003 Dec 15; 102(13):4354-60.
Score: 0.218
-
Erlotinib is not effective in patients with JAK2V617F-positive polycythemia vera. Ann Hematol. 2015 Apr; 94(4):717-9.
Score: 0.119
-
CD169? macrophages provide a niche promoting erythropoiesis under homeostasis and stress. Nat Med. 2013 Apr; 19(4):429-36.
Score: 0.027
-
Aconitase regulation of erythropoiesis correlates with a novel licensing function in erythropoietin-induced ERK signaling. PLoS One. 2011; 6(8):e23850.
Score: 0.024
-
Detection of the JAK2V617F mutation by asymmetric PCR and melt curve analysis. Cancer Biomark. 2007; 3(6):315-24.
Score: 0.017